Search Results

CSL Seqirus, a Global Leader in Pandemic Preparedness and Outbreak Response, Signs an Agreement with the European Commission to Support Pandemic Preparedness Plans

https://newsroom.csl.com/2025-04-29-CSL-Seqirus,-a-Global-Leader-in-Pandemic-Preparedness-and-Outbreak-Response,-Signs-an-Agreement-with-the-European-Commission-to-Support-Pandemic-Preparedness-Plans

CSL Seqirus provides innovative solutions for pandemic preparedness and response.

https://www.csl.com/patients-public-health/vaccines/pandemic-response

CSL Seqirus is a global leader and proud champion of the pandemic preparedness efforts of over 30 governments, and we are pleased to work with the European Commission to deliver this zoonotic vaccine as part of their pandemic preparedness and outbreak response," said Lorna Meldrum, CSL Seqirus, VP Commercial Operations, International & Pandemic Response.

https://newsroom.csl.com/2024-06-11-CSL-Seqirus,-a-Proud-Champion-of-Pandemic-Preparedness,-Signs-an-Agreement-with-the-European-Commission-to-Provide-Pre-Pandemic-Vaccines-to-the-EU

On Pandemic Preparedness

https://newsroom.csl.com/2024-05-30-On-Pandemic-Preparedness

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens

https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics

Cell-based influenza vaccine manufacturing is well suited to enabling pandemic preparedness as it reduces reliance on large volumes of critical materials and is a modern, efficient and highly scalable alternative to traditional manufacturing methods.

https://newsroom.csl.com/2025-10-30-CSL-Seqirus-and-Vaccine-Industrial-Company-sign-landmark-Memorandum-of-Understanding-with-Ministry-of-Health-to-localize-manufacturing-of-cell-based-seasonal-and-pandemic-influenza-vaccines

Steve Marlow, CSL Seqirus General Manager, added "Importantly, it is another step towards our long-term aim to advance public health by developing and commercializing enhanced vaccines for influenza and multi-pathogen pandemic preparedness.

https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology

CSL is committed to pricing practices that reflect the value our products bring to patients and society.

https://www.csl.com/sustainability/healthier-communities/access-and-affordability

We are a diverse collective of people after one goal - to reimagine, reinvent and find new answers that save, improve and protect life.

https://www.csl.com/we-are-csl

CSL Seqirus is a global influenza vaccine provider developing innovative solutions.

https://www.csl.com/patients-public-health/vaccines